期刊
出版社
ELSEVIER
DOI: 10.1016/j.jchromb.2022.123164
关键词
Ceftazidime; Avibactam; Plasma; Dried blood spot; LC-MS/MS
资金
- Pfizer Pharma GmbH, Germany
This study developed a method for the simultaneous quantification of ceftazidime and avibactam, and evaluated dried blood spots (DBS) as a matrix for improved stability of the drugs. The results showed that the stability of ceftazidime and avibactam was better in DBS compared to plasma, extending the maximal transport times to 24 hours for DBS samples.
Ceftazidime is an established third-generation cephalosporin antibiotic frequently administered to intensive care patients. To overcome drug resistance of pathogens, it is combined with the newly developed non-beta-lactam beta-lactamase inhibitor avibactam under the brand name Zavicefta (R). To facilitate therapeutic drug monitoring (TDM), we developed a method for the simultaneous quantification of these substances by LC-MS/MS. A problem for TDM is the low stability of the analytes in plasma, requiring transport times of less than 6 h at 23 degrees C. Thus, we evaluated dried blood spots (DBS) as matrix for better stability. For both analytes, stable isotope labelled internal standards were applied. Plasma samples were prepared by protein precipitation, DBS by liquid extraction. The chromatographic separation took place on a polar-modified C18 column, and detection was achieved by tandem mass spectrometry with ESI ionization in positive mode for ceftazidime and negative mode for avibactam. Calibration was linear in the ranges of 5 - 100 mu g/mL for ceftazidime and 1.25 - 25 mu g/mL for avibactam in plasma and 2.5 - 50 mu g/mL and 0.625 - 12.5 mu g/mL in DBS, respectively. Precision was better than 7 % and accuracy better than 10% for plasma as well as for DBS. The stability of ceftazidime and avibactam was better in DBS than in plasma or full blood, extending maximal transport times at 23 degrees C from 6 h in plasma or full blood to 24 h for DBS samples. However, robust estimation of plasma concentrations from DBS measurements requires validation by future clinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据